Krystal Biotech, Inc. (KRYS)
NASDAQ: KRYS · Real-Time Price · USD
325.42
+5.17 (1.61%)
Oct 20, 2026, 4:00 PM EDT - Market closed
Krystal Biotech Revenue
Krystal Biotech had revenue of $119.22M in the quarter ending June 30, 2026, with 24.14% growth. This brings the company's total for the last twelve months to $440.48M, up 22.63% year-over-year. In the year 2025, Krystal Biotech had annual revenue of $389.13M with 33.94% growth. That makes Krystal Biotech the 11,948th largest company in the world by revenue and 2,370th in the United States.
Revenue (ttm)
$440.48M
Revenue Growth
+22.63%
P/S Ratio
21.87
Revenue / Employee
$1,493,166
Employees
295
Market Cap
9.63B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 389.13M | 98.62M | 33.94% |
| Dec 31, 2024 | 290.52M | 239.82M | 473.02% |
| Dec 31, 2023 | 50.70M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BioMarin Pharmaceutical | 3.41B |
| Madrigal Pharmaceuticals | 1.28B |
| Caris Life Sciences | 989.61M |
| Axsome Therapeutics | 776.57M |
| Arrowhead Pharmaceuticals | 669.50M |
| Twist Bioscience | 431.80M |
| Protagonist Therapeutics | 281.99M |
| ImmunityBio | 165.79M |
KRYS News
- 5 days ago - Krystal Biotech price target raised to $416 from $386 at Citi - TheFly
- 5 days ago - Krystal Biotech provides clinical data for KB113 program - TheFly
- 5 days ago - Krystal Biotech Announces Positive Clinical Data for New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression in Patients with Gorlin Syndrome - GlobeNewsWire
- 26 days ago - Krystal Biotech resumed with a Buy at Goldman Sachs - TheFly
- 4 weeks ago - Krystal Biotech price target raised to $400 from $392 at BofA - TheFly
- 5 weeks ago - Krystal Biotech Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 6 weeks ago - Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Krystal Biotech initiated with an Outperform at RBC Capital - TheFly